{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:44:17Z","timestamp":1790142257895,"version":"4.0.1"},"reference-count":140,"publisher":"Bioscientifica","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>Langerhans cell histiocytosis (LCH) is a rare disease of not well-defined etiology that involves immune cell activation and frequently affects the skeleton. Bone involvement in LCH usually presents in the form of osteolytic lesions along with low bone mineral density. Various molecules involved in bone metabolism are implicated in the pathogenesis of LCH or may be affected during the course of the disease, including interleukins (ILs), tumor necrosis factor \u03b1, receptor activator of NF-\u03baB (RANK) and its soluble ligand RANKL, osteoprotegerin (OPG), periostin and sclerostin. Among them IL-17A, periostin and RANKL have been proposed as potential serum biomarkers for LCH, particularly as the interaction between RANK, RANKL and OPG not only regulates bone homeostasis through its effects on the osteoclasts but also affects the activation and survival of immune cells. Significant changes in circulating and lesional RANKL levels have been observed in LCH patients irrespective of bone involvement. Standard LCH management includes local or systematic administration of corticosteroids and chemotherapy. Given the implication of RANK, RANKL and OPG in the pathogenesis of the disease and the osteolytic nature of bone lesions, agents aiming at inhibiting the RANKL pathway and\/or osteoclastic activation, such as bisphosphonates and denosumab, may have a role in the therapeutic approach of LCH although further clinical investigation is warranted.<\/jats:p>","DOI":"10.1530\/ec-18-0186","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T13:15:38Z","timestamp":1530537338000},"page":"R246-R253","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":22,"title":["Bone metabolism in Langerhans cell histiocytosis"],"prefix":"10.1530","volume":"7","author":[{"given":"Athanasios D","family":"Anastasilakis","sequence":"first","affiliation":[{"name":"1Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Tsoli","sequence":"additional","affiliation":[{"name":"21st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[{"name":"21st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[{"name":"3Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref211","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1182\/asheducation-2015.1.559","article-title":"Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders","volume":"2015","year":"2015","journal-title":"Hematology American Society of Hematology Education Program"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.abb.2014.06.003","article-title":"The immune system, bone and RANKL","volume":"561","year":"2014","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.hoc.2015.06.006","article-title":"Strategies for the prevention of central nervous system complications in patients with Langerhans cell histiocytosis: the problem of neurodegenerative syndrome","volume":"29","year":"2015","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/pbc.21782","article-title":"Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis","volume":"52","year":"2009","journal-title":"Pediatric Blood and Cancer"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1084\/jem.20041785","article-title":"Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis","volume":"201","year":"2005","journal-title":"Journal of Experimental Medicine"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1182\/asheducation-2015.1.559","article-title":"Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders","volume":"2015","year":"2015","journal-title":"Hematology American Society of Hematology Education Program"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1592\/phco.28.5.667","article-title":"Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates","volume":"28","year":"2008","journal-title":"Pharmacotherapy"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.mph.0000154069.81149.5f","article-title":"The role of vascular endothelial growth factor in Langerhans cell histiocytosis","volume":"27","year":"2005","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/pbc.21782","article-title":"Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis","volume":"52","year":"2009","journal-title":"Pediatric Blood and Cancer"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors \u2013 a systematic review","volume":"62","year":"2018","journal-title":"Cancer Treatment Reviews"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1084\/jem.186.12.2075","article-title":"TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor","volume":"186","year":"1997","journal-title":"Journal of Experimental Medicine"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/pbc.21504","article-title":"Incidence of Langerhans cell histiocytosis in children: a population-based study","volume":"51","year":"2008","journal-title":"Pediatric Blood and Cancer"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1359\/jbmr.2002.17.11.1926","article-title":"Bisphosphonate induces remission of refractory osteolysis in langerhans cell histiocytosis","volume":"17","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/pbc.22703","article-title":"Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan","volume":"56","year":"2011","journal-title":"Pediatric Blood and Cancer"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1684\/ecn.2011.0290","article-title":"Langerhans cell histiocytosis: a cytokine\/chemokine-mediated disorder?","volume":"22","year":"2011","journal-title":"European Cytokine Network"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/PAS.0b013e31815b212b","article-title":"Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders","volume":"32","year":"2008","journal-title":"American Journal of Surgical Pathology"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.4049\/jimmunol.177.5.3314","article-title":"Immune interactions with CD4+ T cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells","volume":"177","year":"2006","journal-title":"Journal of Immunology"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","year":"2013","journal-title":"Pediatric Blood and Cancer"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathol-020712-163959","article-title":"Pathogenesis of Langerhans cell histiocytosis","volume":"8","year":"2013","journal-title":"Annual Review of Pathology"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ctrv.2010.02.012","article-title":"Langerhans cell histiocytosis: current concepts and treatments","volume":"36","year":"2010","journal-title":"Cancer Treatment Reviews"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0959-8049(99)00039-8","article-title":"The histiocytoses: the fall of the Tower of Babel","volume":"35","year":"1999","journal-title":"European Journal of Cancer"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1084\/jem.20041785","article-title":"Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis","volume":"201","year":"2005","journal-title":"Journal of Experimental Medicine"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.matbio.2014.04.007","article-title":"Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments","volume":"37","year":"2014","journal-title":"Matrix Biology"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-0-12-417028-5.00005-3","article-title":"Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases","volume":"120","year":"2013","journal-title":"Advances in Immunology"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood.V90.9.3245","article-title":"Dendritic cells: unique leukocyte populations which control the primary immune response","volume":"90","year":"1997","journal-title":"Blood"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1074-7613(00)80160-0","article-title":"Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules","volume":"12","year":"2000","journal-title":"Immunity"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"e43257","DOI":"10.1371\/journal.pone.0043257","article-title":"Optimal therapy for adults with Langerhans cell histiocytosis bone lesions","volume":"7","year":"2012","journal-title":"PLoS ONE"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.hoc.2015.06.006","article-title":"Strategies for the prevention of central nervous system complications in patients with Langerhans cell histiocytosis: the problem of neurodegenerative syndrome","volume":"29","year":"2015","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","article-title":"The molecular understanding of osteoclast differentiation","volume":"40","year":"2007","journal-title":"Bone"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/pbc.22703","article-title":"Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan","volume":"56","year":"2011","journal-title":"Pediatric Blood and Cancer"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00774-008-0001-2","article-title":"Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis","volume":"27","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"ref861","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jc.2011-2962","article-title":"Serum osteoprotegerin levels in adults with Langerhans cell histiocytosis of and https org","author":"RANKL","journal-title":"Journal Clinical Endocrinology Metabolism"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2014.10.045","article-title":"Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis","volume":"73","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"key":"ref691","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","year":"2017","journal-title":"Oncology Reviews"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0959-8049(03)00672-5","article-title":"Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society","volume":"39","year":"2003","journal-title":"European Journal of Cancer"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pbc.20595","article-title":"High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis","volume":"47","year":"2006","journal-title":"Pediatric Blood and Cancer"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/pbc.21504","article-title":"Incidence of Langerhans cell histiocytosis in children: a population-based study","volume":"51","year":"2008","journal-title":"Pediatric Blood and Cancer"},{"key":"ref561","first-page":"157","article-title":"Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic\/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society","volume":"29","year":"1997","journal-title":"Medical and Pediatric Oncology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0889-8588(05)70509-8","article-title":"Langerhans cell histiocytosis in adults","volume":"12","year":"1998","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/pbc.23166","article-title":"Reduced bone mineral density in adult patients with Langerhans cell histiocytosis","volume":"58","year":"2012","journal-title":"Pediatric Blood and Cancer"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1084\/jem.186.12.2075","article-title":"TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor","volume":"186","year":"1997","journal-title":"Journal of Experimental Medicine"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2015.12.014","article-title":"Periostin action in bone","volume":"432","year":"2016","journal-title":"Molecular and Cellular Endocrinology"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2014.10.045","article-title":"Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis","volume":"73","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.metabol.2017.01.004","article-title":"Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis","volume":"69","year":"2017","journal-title":"Metabolism"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.tem.2007.06.003","article-title":"Endocrine manifestations in Langerhans cell histiocytosis","volume":"18","year":"2007","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function","volume":"390","year":"1997","journal-title":"Nature"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2796.1989.tb00038.x","article-title":"Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone","volume":"225","year":"1989","journal-title":"Journal of Internal Medicine"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.abb.2014.06.003","article-title":"The immune system, bone and RANKL","volume":"561","year":"2014","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ctrv.2010.02.012","article-title":"Langerhans cell histiocytosis: current concepts and treatments","volume":"36","year":"2010","journal-title":"Cancer Treatment Reviews"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/pbc.20021","article-title":"Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group","volume":"42","year":"2004","journal-title":"Pediatric Blood and Cancer"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2015.12.014","article-title":"Periostin action in bone","volume":"432","year":"2016","journal-title":"Molecular and Cellular Endocrinology"},{"key":"ref1071","first-page":"282","article-title":"Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis of and https org","journal-title":"Journal Clinical Endocrinology Metabolism"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2011.150","article-title":"IL-17A in LCH: systemic biomarker, local factor, or none of the above?","volume":"19","year":"2011","journal-title":"Molecular Therapy"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2796.1989.tb00038.x","article-title":"Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone","volume":"225","year":"1989","journal-title":"Journal of Internal Medicine"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/13543780903048929","article-title":"RANKL inhibition for the management of patients with benign metabolic bone disorders","volume":"18","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s13244-013-0271-7","article-title":"Skeletal involvement in Langerhans cell histiocytosis","volume":"4","year":"2013","journal-title":"Insights into Imaging"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems","volume":"7","year":"2007","journal-title":"Nature Reviews Immunology"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"key":"ref941","first-page":"1","article-title":"Trametinib-induced remission of an MEK1-mutated Langerhans cell histiocytosis","volume":"1","year":"2017","journal-title":"JCO Clinical Cancer Informatics"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","year":"2003","journal-title":"EMBO Journal"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"e2016033","DOI":"10.4084\/mjhid.2016.033","article-title":"Bisphosphonates in Langerhans cell histiocytosis: an international retrospective case series","volume":"8","year":"2016","journal-title":"Mediterranean Journal of Hematology and Infectious Diseases"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1684\/ecn.2011.0290","article-title":"Langerhans cell histiocytosis: a cytokine\/chemokine-mediated disorder?","volume":"22","year":"2011","journal-title":"European Cytokine Network"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.mph.0000168725.57143.52","article-title":"Immunohistochemical detection of the apoptosis-related proteins FADD, FLICE, and FLIP in Langerhans cell histiocytosis","volume":"27","year":"2005","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2559.2004.01875.x","article-title":"Expression of apoptosis-regulatory proteins in lesions of pulmonary Langerhans cell histiocytosis","volume":"45","year":"2004","journal-title":"Histopathology"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2011.150","article-title":"IL-17A in LCH: systemic biomarker, local factor, or none of the above?","volume":"19","year":"2011","journal-title":"Molecular Therapy"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.hoc.2015.06.001","article-title":"Nosology and pathology of Langerhans cell histiocytosis","volume":"29","year":"2015","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.4049\/jimmunol.177.5.3314","article-title":"Immune interactions with CD4+ T cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells","volume":"177","year":"2006","journal-title":"Journal of Immunology"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems","volume":"7","year":"2007","journal-title":"Nature Reviews Immunology"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0889-8588(05)70509-8","article-title":"Langerhans cell histiocytosis in adults","volume":"12","year":"1998","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.metabol.2017.01.004","article-title":"Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis","volume":"69","year":"2017","journal-title":"Metabolism"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood.V90.9.3245","article-title":"Dendritic cells: unique leukocyte populations which control the primary immune response","volume":"90","year":"1997","journal-title":"Blood"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.metabol.2015.07.011","article-title":"Novel therapies for osteoporosis","volume":"64","year":"2015","journal-title":"Metabolism"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jc.2011-2962","article-title":"Serum osteoprotegerin levels in adults with Langerhans cell histiocytosis of and https org","author":"RANKL","journal-title":"Journal Clinical Endocrinology Metabolism"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1073\/pnas.1116770109","article-title":"Langerhans cells down-regulate inflammation-driven alveolar bone loss","volume":"109","year":"2012","journal-title":"PNAS"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-8-72","article-title":"Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net","volume":"8","year":"2013","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200107193450318","article-title":"Pamidronate for bone pain from osteolytic lesions in Langerhans\u2019-cell histiocytosis","volume":"345","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.matbio.2014.04.007","article-title":"Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments","volume":"37","year":"2014","journal-title":"Matrix Biology"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejim.2016.11.015","article-title":"Periostin: the bone and beyond","volume":"38","year":"2017","journal-title":"European Journal of Internal Medicine"},{"key":"ref1401","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","year":"2017","journal-title":"Oncology Reviews"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejim.2016.11.015","article-title":"Periostin: the bone and beyond","volume":"38","year":"2017","journal-title":"European Journal of Internal Medicine"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathol-020712-163959","article-title":"Pathogenesis of Langerhans cell histiocytosis","volume":"8","year":"2013","journal-title":"Annual Review of Pathology"},{"key":"ref281","first-page":"252","article-title":"The origin of the osteoclast","volume":"145","year":"1979","journal-title":"Clinical Orthopaedics and Related Research"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1073\/pnas.1116770109","article-title":"Langerhans cells down-regulate inflammation-driven alveolar bone loss","volume":"109","year":"2012","journal-title":"PNAS"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/PAS.0b013e31815b212b","article-title":"Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders","volume":"32","year":"2008","journal-title":"American Journal of Surgical Pathology"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"e43257","DOI":"10.1371\/journal.pone.0043257","article-title":"Optimal therapy for adults with Langerhans cell histiocytosis bone lesions","volume":"7","year":"2012","journal-title":"PLoS ONE"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1359\/jbmr.2001.16.1.97","article-title":"Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis","volume":"16","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1210\/jc.2013-3893","article-title":"Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2011.239","article-title":"Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?","volume":"20","year":"2012","journal-title":"Molecular Therapy"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1592\/phco.28.5.667","article-title":"Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates","volume":"28","year":"2008","journal-title":"Pharmacotherapy"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(06)54001-X","article-title":"Biology of Langerhans cells and Langerhans cell histiocytosis","volume":"254","year":"2006","journal-title":"International Review of Cytology"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.4049\/jimmunol.181.2.1507","article-title":"IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model","volume":"181","year":"2008","journal-title":"Journal of Immunology"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00256-006-0193-2","article-title":"Langerhans cell histiocytosis","volume":"36","year":"2007","journal-title":"Skeletal Radiology"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","year":"2003","journal-title":"EMBO Journal"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.metabol.2017.03.017","article-title":"Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity","volume":"71","year":"2017","journal-title":"Metabolism"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(06)54001-X","article-title":"Biology of Langerhans cells and Langerhans cell histiocytosis","volume":"254","year":"2006","journal-title":"International Review of Cytology"},{"key":"ref231","first-page":"1","article-title":"Trametinib-induced remission of an MEK1-mutated Langerhans cell histiocytosis","volume":"1","year":"2017","journal-title":"JCO Clinical Cancer Informatics"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","article-title":"Transforming growth factor beta in tissue fibrosis","volume":"331","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.mph.0000168725.57143.52","article-title":"Immunohistochemical detection of the apoptosis-related proteins FADD, FLICE, and FLIP in Langerhans cell histiocytosis","volume":"27","year":"2005","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","article-title":"The molecular understanding of osteoclast differentiation","volume":"40","year":"2007","journal-title":"Bone"},{"key":"ref361","first-page":"282","article-title":"Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis of and https org","journal-title":"Journal Clinical Endocrinology Metabolism"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/pbc.23166","article-title":"Reduced bone mineral density in adult patients with Langerhans cell histiocytosis","volume":"58","year":"2012","journal-title":"Pediatric Blood and Cancer"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1210\/jc.2013-3893","article-title":"Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/mi.2016.61","article-title":"Periostin regulates fibrocyte function to promote myofibroblast differentiation and lung fibrosis","volume":"10","year":"2017","journal-title":"Mucosal Immunology"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/adc.2003.036590","article-title":"Bisphosphonate treatment of bone disease","volume":"90","year":"2005","journal-title":"Archives of Disease in Childhood"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.metabol.2017.03.017","article-title":"Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity","volume":"71","year":"2017","journal-title":"Metabolism"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/adc.2003.036590","article-title":"Bisphosphonate treatment of bone disease","volume":"90","year":"2005","journal-title":"Archives of Disease in Childhood"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.4049\/jimmunol.181.2.1507","article-title":"IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model","volume":"181","year":"2008","journal-title":"Journal of Immunology"},{"key":"ref831","first-page":"4195","article-title":"Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment","volume":"94","year":"1999","journal-title":"Blood"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2011.239","article-title":"Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?","volume":"20","year":"2012","journal-title":"Molecular Therapy"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.mph.0000154069.81149.5f","article-title":"The role of vascular endothelial growth factor in Langerhans cell histiocytosis","volume":"27","year":"2005","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pbc.20595","article-title":"High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis","volume":"47","year":"2006","journal-title":"Pediatric Blood and Cancer"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors \u2013 a systematic review","volume":"62","year":"2018","journal-title":"Cancer Treatment Reviews"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200107193450318","article-title":"Pamidronate for bone pain from osteolytic lesions in Langerhans\u2019-cell histiocytosis","volume":"345","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-8-72","article-title":"Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net","volume":"8","year":"2013","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"ref461","first-page":"145","article-title":"Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment","volume":"46","year":"2014","journal-title":"Hormone and Metabolic Research"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","article-title":"Transforming growth factor beta in tissue fibrosis","volume":"331","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.metabol.2015.07.011","article-title":"Novel therapies for osteoporosis","volume":"64","year":"2015","journal-title":"Metabolism"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/mi.2016.61","article-title":"Periostin regulates fibrocyte function to promote myofibroblast differentiation and lung fibrosis","volume":"10","year":"2017","journal-title":"Mucosal Immunology"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/pbc.20021","article-title":"Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group","volume":"42","year":"2004","journal-title":"Pediatric Blood and Cancer"},{"key":"ref121","first-page":"4195","article-title":"Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment","volume":"94","year":"1999","journal-title":"Blood"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00774-008-0001-2","article-title":"Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis","volume":"27","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1074-7613(00)80160-0","article-title":"Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules","volume":"12","year":"2000","journal-title":"Immunity"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.tem.2007.06.003","article-title":"Endocrine manifestations in Langerhans cell histiocytosis","volume":"18","year":"2007","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.hoc.2015.06.001","article-title":"Nosology and pathology of Langerhans cell histiocytosis","volume":"29","year":"2015","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00256-006-0193-2","article-title":"Langerhans cell histiocytosis","volume":"36","year":"2007","journal-title":"Skeletal Radiology"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1359\/jbmr.2002.17.11.1926","article-title":"Bisphosphonate induces remission of refractory osteolysis in langerhans cell histiocytosis","volume":"17","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function","volume":"390","year":"1997","journal-title":"Nature"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s13244-013-0271-7","article-title":"Skeletal involvement in Langerhans cell histiocytosis","volume":"4","year":"2013","journal-title":"Insights into Imaging"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-0-12-417028-5.00005-3","article-title":"Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases","volume":"120","year":"2013","journal-title":"Advances in Immunology"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/13543780903048929","article-title":"RANKL inhibition for the management of patients with benign metabolic bone disorders","volume":"18","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"ref1271","first-page":"157","article-title":"Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic\/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society","volume":"29","year":"1997","journal-title":"Medical and Pediatric Oncology"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"e2016033","DOI":"10.4084\/mjhid.2016.033","article-title":"Bisphosphonates in Langerhans cell histiocytosis: an international retrospective case series","volume":"8","year":"2016","journal-title":"Mediterranean Journal of Hematology and Infectious Diseases"},{"key":"ref1171","first-page":"145","article-title":"Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment","volume":"46","year":"2014","journal-title":"Hormone and Metabolic Research"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1359\/jbmr.2001.16.1.97","article-title":"Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis","volume":"16","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0959-8049(99)00039-8","article-title":"The histiocytoses: the fall of the Tower of Babel","volume":"35","year":"1999","journal-title":"European Journal of Cancer"},{"key":"ref991","first-page":"252","article-title":"The origin of the osteoclast","volume":"145","year":"1979","journal-title":"Clinical Orthopaedics and Related Research"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","year":"2013","journal-title":"Pediatric Blood and Cancer"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2559.2004.01875.x","article-title":"Expression of apoptosis-regulatory proteins in lesions of pulmonary Langerhans cell histiocytosis","volume":"45","year":"2004","journal-title":"Histopathology"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0959-8049(03)00672-5","article-title":"Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society","volume":"39","year":"2003","journal-title":"European Journal of Cancer"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/7\/7\/EC-18-0186.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/7\/7\/EC-18-0186.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:42:57Z","timestamp":1784554977000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/7\/7\/R246-R253\/340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":140,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.1530\/ec-18-0186","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}